Manisha Bhutani

5.4k total citations
144 papers, 2.8k citations indexed

About

Manisha Bhutani is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Manisha Bhutani has authored 144 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Hematology, 64 papers in Oncology and 57 papers in Molecular Biology. Recurrent topics in Manisha Bhutani's work include Multiple Myeloma Research and Treatments (91 papers), Protein Degradation and Inhibitors (37 papers) and CAR-T cell therapy research (15 papers). Manisha Bhutani is often cited by papers focused on Multiple Myeloma Research and Treatments (91 papers), Protein Degradation and Inhibitors (37 papers) and CAR-T cell therapy research (15 papers). Manisha Bhutani collaborates with scholars based in United States, India and Spain. Manisha Bhutani's co-authors include Saad Z. Usmani, Ashutosh Pathak, Peter M. Voorhees, Vinod Kochupillai, Sushovan Guha, Gautam Sethi, Bharat B. Aggarwal, S. Asha Nair, Shebli Atrash and Elyn Riedel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Manisha Bhutani

133 papers receiving 2.8k citations

Peers

Countries citing papers authored by Manisha Bhutani

Since Specialization

Citations

This map shows the geographic impact of Manisha Bhutani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manisha Bhutani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manisha Bhutani more than expected).

Fields of papers citing papers by Manisha Bhutani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manisha Bhutani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manisha Bhutani. The network helps show where Manisha Bhutani may publish in the future.

Co-authorship network of co-authors of Manisha Bhutani

This figure shows the co-authorship network connecting the top 25 collaborators of Manisha Bhutani. A scholar is included among the top collaborators of Manisha Bhutani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manisha Bhutani. Manisha Bhutani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Cindy Varga, Myra Robinson, Vikas A. Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, (unknown), Christopher J. Ferreri, (unknown), Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph	0
2	Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution 2024 ·Blood ·Cindy Varga, (unknown), (unknown), Manisha Bhutani, Barry Paul, Shebli Atrash, (unknown), Christopher J. Ferreri	1
3	Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study) 2024 ·Life ·Hamid Ehsan, Myra Robinson, Peter M. Voorhees, (unknown), (unknown), Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda‐Roman, (unknown), (unknown)	2
4	MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma 2024 ·Blood Advances ·Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry Paul, Fei Guo, Jason M. Grayson, (unknown), Mauricio Pineda‐Roman, Cindy Varga, (unknown), Christopher J. Ferreri, (unknown), (unknown), (unknown), (unknown), James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani	3
5	Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Alfred L. Garfall, Ajay K. Nooka, (unknown), Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G Martin, Laura Rosiñol, María-Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Amrita Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana	0
6	MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Alfred L. Garfall, Ajay K. Nooka, (unknown), Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G Martin, Laura Rosiñol, María-Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Amrita Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana	8
7	P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Rakesh Popat, Ajay K. Nooka, Niels W.C.J. van de Donk, Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G. Martin, Laura Rosiñol, (unknown), Nizar J. Bahlis, Alfred L. Garfall, Britta Besemer, Joaquín Martínez‐López, (unknown), Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana	1
8	A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Manisha Bhutani, David Foureau, Myra Robinson, Fei Guo, (unknown), Shebli Atrash, Barry Paul, Cindy Varga, (unknown), Mauricio Pineda‐Roman, (unknown), James T. Symanowski, (unknown), (unknown), Lawrence J. Druhan, Peter M. Voorhees, Saad Z. Usmani	2
9	Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug–Based Regimens 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Jai N. Patel, Myra Robinson, Megan H. Jagosky, (unknown), Justin Arnall, (unknown), (unknown), Shebli Atrash, Barry Paul, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani	5
10	Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Donald C. Moore, Justin Arnall, (unknown), (unknown), (unknown), (unknown), Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani	10
11	Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Issam S. Hamadeh, (unknown), Justin Arnall, (unknown), (unknown), (unknown), (unknown), (unknown), Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani	15
12	Viral, immunologic, and clinical features of primary effusion lymphoma 2019 ·Blood ·Kathryn Lurain, Mark N. Polizzotto, Karen Aleman, Manisha Bhutani, Kathleen M. Wyvill, Priscila Gonçalves, Ramya Ramaswami, Vickie Marshall, Wendell Miley, Seth M. Steinberg, Richard F. Little, Wyndham H. Wilson, Armando Filie, Stefania Pittaluga, Elaine S. Jaffe, Denise Whitby, Robert Yarchoan, Thomas S. Uldrick	83
13	Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience 2019 ·Diseases of the Esophagus ·K. G. Mitchell, David B. Nelson, Erin M. Corsini, Ara A. Vaporciyan, Mara B. Antonoff, Reza J. Mehran, David C. Rice, Jack A. Roth, Boris Sepesi, G. Walsh, Manisha Bhutani, Dipen M. Maru, (unknown), (unknown), Jaffer A. Ajani, Stephen G. Swisher, Wayne L. Hofstetter	25
14	Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma 2017 ·Blood ·Myra Robinson, Shebli Atrash, (unknown), Jared Block, Edward H. Lipford, (unknown), (unknown), (unknown), (unknown), Qing Zhang, David Foureau, (unknown), (unknown), James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Peter M. Voorhees, Saad Z. Usmani, Manisha Bhutani	0
15	Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases 2017 ·Blood ·Manisha Bhutani, David Foureau, Qing Zhang, Myra Robinson, (unknown), Nury Steuerwald, Lawrence J. Druhan, Fei Guo, (unknown), (unknown), (unknown), Shebli Atrash, (unknown), (unknown), James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Peter M. Voorhees, Saad Z. Usmani	2
16	Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma 2017 ·Blood ·David Foureau, Manisha Bhutani, Qing Zhang, Myra Robinson, (unknown), Nury Steuerwald, Lawrence J. Druhan, Fei Guo, (unknown), (unknown), (unknown), Shebli Atrash, (unknown), (unknown), James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Peter M. Voorhees, Saad Z. Usmani	1
17	Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma 2017 ·Blood ·Shebli Atrash, Myra Robinson, (unknown), (unknown), (unknown), (unknown), (unknown), Qing Zhang, Edward H. Lipford, Jared Block, (unknown), James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Peter M. Voorhees, Saad Z. Usmani, Manisha Bhutani	1
18	Oral Epithelium as a Surrogate Tissue for Assessing Smoking-Induced Molecular Alterations in the Lungs 2008 ·Cancer Prevention Research ·Manisha Bhutani, Ashutosh Pathak, You-Hong Fan, Diane D. Liu, J. Jack Lee, Hongli Tang, Jonathan M. Kurie, Rodolfo C. Morice, Edward S. Kim, Waun Ki Hong, Li Mao	70
19	ΔDNMT3B Variants Regulate DNA Methylation in a Promoter-Specific Manner 2007 ·Cancer Research ·Jie Wang, Manisha Bhutani, Ashutosh Pathak, Wenhua Lang, Hening Ren, Jaroslav Jelı́nek, Rong He, Lanlan Shen, Jean‐Pierre J. Issa, Li Mao	47
20	Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells 2007 ·Molecular Cancer Research ·Ashutosh Pathak, Manisha Bhutani, S. Asha Nair, Kwang Seok Ahn, Arup Chakraborty, Humam Kadara, Sushovan Guha, Gautam Sethi, Bharat B. Aggarwal	196

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact